Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 12 Lung Neoplasms 4 Neoplasms 2 Solid Tumors 1 Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 2a 1 Lymphoma, Large-Cell, Anaplastic 1 Lung Diseases 1 Genomic Instability 1 Central Nervous System Neoplasms 1 Carcinoma, Hepatocellular 1 Brain Neoplasms 1 Bone Neoplasms 1 Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1

Interventions

atezolizumab 1 alectinib 1 Vemurafenib 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Genomic Instability × alectinib × 90 days × Clear all

NCT02314481 2026-05-04

DARWINII

University College, London

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Genomic Instability

Data powered by HemOnc (CC BY 4.0) Colophon ⚡